14 Years of Actorius: A Journey of Innovation & Impact

On 15 August, Actorius Innovations and Research celebrated its 14th Foundation Day—a milestone that marks more than another year on the calendar. It represents years of scientific exploration, technological development, clinical collaboration, and an unwavering focus on advancing cancer diagnostics.

What began as an idea has grown into a journey focused on one of the most important challenges in oncology: understanding cancer at the cellular level and developing technologies that can help clinicians monitor how the disease evolves over time.

From circulating tumor cells (CTCs) and liquid biopsy to technologies designed to support more informed approaches to cancer monitoring and metastasis research, the journey has always been driven by a simple belief: meaningful innovation in healthcare must ultimately translate into meaningful value for patients and clinicians.

A Milestone Year for Actorius

This Foundation Day feels particularly significant because this year, three important milestones came together:

CDSCO Approved

OncoDiscover® became the first and only CDSCO-approved clinical CTC liquid biopsy test in India, enabling standardized clinical use of CTC-based cancer monitoring.

ISO 13485:2016 Certified

Actorius' medical device Quality Management System complies with ISO 13485:2016, reflecting internationally recognized standards for the design, development, manufacturing, and regulatory compliance of medical devices.

NABL Accredited

Testing is performed in an NABL-accredited laboratory, reinforcing technical competence, standardized laboratory processes, and quality in medical testing.

Together, these milestones represent different dimensions of what it takes to move a healthcare innovation from scientific concept toward clinical application—regulatory validation, quality systems, and laboratory excellence.

But certifications are milestones, not the mission.

The Mission Remains Bigger Than the Milestones

The purpose behind Actorius has remained consistent:

Build meaningful science.Translate it into useful technology.And ultimately help give patients a better chance against cancer.

Our work with CTC technologies reflects this approach.

CTCs are cancer cells that can enter the bloodstream from tumors. Studying these cells can provide valuable biological information about cancer and how it changes over time. This has made CTCs an important area of research in liquid biopsy and cancer monitoring.

Through OncoDiscover® CTC testing, Actorius is bringing CTC-based testing into clinical practice in India, with capabilities that include CTC enumeration and protein expression analysis such as PD-L1 and HER2.

At the same time, our research and development continues to explore what may be possible beyond conventional testing.

OncoMetastat®, our patented investigational platform for extracorporeal blood processing, is being evaluated for its potential applications in metastasis research and future cancer care strategies.

Designed to selectively isolate and analyze CTCs while preserving blood quality, the platform reflects our continued effort to explore new approaches to understanding cancer progression.

From India, With a Global Scientific Ambition

Our journey is rooted in India, but the questions we are working to address are global.

Cancer remains one of the most complex challenges in medicine. Better outcomes will require continued progress across diagnostics, monitoring, treatment, research, and clinical decision-making.

For Actorius Innovations and Research, being built in India means more than developing technologies locally. It means contributing Indian scientific and engineering capabilities to a field with global significance.

Our goal is to continue building technologies that are scientifically rigorous, clinically relevant, and capable of contributing to the future of cancer care.

13 Years Completed. The Journey Continues.

As we celebrate our 14th Foundation Day, we look back with gratitude—but also forward with ambition.

A heartfelt thank you to our scientists, clinicians, collaborators, advisors, investors, partners, and every member of the Actorius team who has contributed to this journey.

Every experiment, clinical collaboration, regulatory milestone, publication, prototype, conversation, and challenge has helped shape where we are today.

13 years completed. We are only getting started.

Here’s to the next chapter of science, innovation, and the pursuit of better possibilities in cancer care.

Happy Foundation Day, Team Actorius. 🧬🔬🚀